These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 10519983

  • 1. The impact of new-variant Creutzfeldt-Jakob disease on blood transfusion practice.
    Turner M.
    Br J Haematol; 1999 Sep; 106(4):842-50. PubMed ID: 10519983
    [No Abstract] [Full Text] [Related]

  • 2. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components.
    Hewitt PE, Llewelyn CA, Mackenzie J, Will RG.
    Vox Sang; 2006 Nov; 91(4):348. PubMed ID: 17105612
    [No Abstract] [Full Text] [Related]

  • 3. Recipients of blood or blood products "at vCJD risk".
    Bird SM.
    BMJ; 2004 Jan 17; 328(7432):118-9. PubMed ID: 14726314
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML, Ludlam CA.
    Br J Haematol; 2009 Jan 17; 144(1):14-23. PubMed ID: 18950452
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The quandary of Creutzfeldt-Jakob disease.
    Larke B.
    CMAJ; 1998 Oct 06; 159(7):789-92. PubMed ID: 9805025
    [No Abstract] [Full Text] [Related]

  • 11. Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion.
    Wkly Epidemiol Rec; 2000 Nov 24; 75(47):377-9. PubMed ID: 11144617
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products.
    Prowse C, Cuthbertson B, Turner M.
    Haemophilia; 2011 Jul 24; 17(4):703. PubMed ID: 21362112
    [No Abstract] [Full Text] [Related]

  • 14. Blood-transmitted prions and variant Creutzfeldt-Jakob disease.
    Grady GF, Vyas GN.
    Biologicals; 2007 Apr 24; 35(2):75-7. PubMed ID: 17317213
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The pathophysiology of variant Creutzfeldt-Jacob disease: the hypotheses behind concerns for blood components and products.
    Burthem J, Roberts DJ.
    Br J Haematol; 2003 Jul 24; 122(1):3-9. PubMed ID: 12823340
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.